Chronic cough, defined as a cough persisting for eight weeks or longer, presents a significant diagnostic and therapeutic challenge in clinical practice. It not only affects the quality of life of patients but also often eludes precise diagnosis and effective treatment.
Common etiologies of chronic cough include upper airway cough syndrome (UACS), gastroesophageal reflux disease (GERD), and asthma. However, the pathophysiology is multifactorial, involving mechanisms such as heightened cough reflex sensitivity, neurogenic inflammation, and eosinophilic airway inflammation.
An organized, systematic approach is crucial in diagnosing chronic cough. Initial evaluation should include a thorough history and physical examination, focusing on identifying common causes and risk factors. If the initial evaluation is unremarkable, further diagnostic testing such as chest radiography, spirometry, and bronchoprovocation testing may be required.
Treatment should be tailored based on the underlying cause. Empirical treatment trials for UACS, GERD, and asthma may be considered. If no specific cause is identified, symptomatic treatment with cough suppressants and neuromodulators may be beneficial. Refractory cases may require referral to a specialist.
Emerging therapies targeting the neural pathways of cough, such as P2X3 receptor antagonists, have shown promising results in recent clinical trials. These novel therapies may play a significant role in the management of refractory chronic cough in the future.
In conclusion, chronic cough is a complex clinical entity that requires a comprehensive, systematic approach for effective diagnosis and management. Understanding the etiology, pathophysiology, and treatment options is vital for optimal patient care. The advent of novel therapies offers hope for those with refractory chronic cough, signifying a promising future in its management.
1.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
2.
Advances in "next generation" photoactive cancer therapy
3.
Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.
4.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
5.
FDA Approves New Bladder Cancer First-Line Standard of Care.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Contemporary Trends in Oncology and Patient Outcomes
5.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation